Detalhe da pesquisa
1.
Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
Nat Cancer
; 2024 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38565920
2.
Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.
Cell Rep
; 42(4): 112297, 2023 04 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36961816
3.
Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4.
J Med Chem
; 63(21): 12542-12573, 2020 11 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32930584
4.
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.
Mol Cancer Ther
; 18(12): 2194-2206, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31409633
5.
Author Correction: Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
Nat Cancer
; 2024 Jun 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38886525
6.
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.
Cancer Discov
; 7(3): 252-263, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28034880
7.
Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors.
PLoS One
; 8(10): e77652, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24204904
8.
FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.
Cancer Discov
; 2(12): 1118-33, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23002168
9.
Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth.
Cancer Discov
; 2(10): 948-59, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22874768
10.
Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.
J Med Chem
; 54(20): 7066-83, 2011 Oct 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-21936542
11.
FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone.
J Bone Miner Res
; 26(10): 2486-97, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21812026